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Multiple myeloma (MM) is a malignant disease characterized by the clonal proliferation of plasma cells within the bone marrow.
Several cytokines have been demonstrated to be involved in the control of growth, progression, and dissemination of MM. We de-
termined serum levels of interleukin-1β (IL-1β), soluble interleukin-2 receptor (sIL-2R), interleukin-6 (IL-6), interleukin-8 (IL-8),
t u m o rn ec r o si sf act o r -α (TNF-α),and C-reactive protein (CRP)in14 newly diagnosed MM patients.The median age of the patients
was 63.4 ± 10.8 years and all of the patients were stage III (classiﬁed according to the Durie-Salmon classiﬁcation). The same pa-
rameters were measured in 15 healthy controls. In addition, we also examined the eﬀects of vincristine-adriamycin-dexamethasone
(VAD) therapy on the same parameters and mediators as well as the relationship among the parameters in the same patient groups.
The serum concentrations of TNF-α,I L - 1 β, sIL-2R, IL-6, IL-8, and CRP (18.6 ± 3.7pg/mL,10.1 ± 2.8pg/mL, 730 ± 220U/mL,
11.4 ± 3.3pg/mL,23.9 ± 8.3pg/mL,and49.9 ± 19.5mg/dL, resp) were signiﬁcantly higher in newly diagnosed MM patients than
in healthy controls (P<. 0001). All of the parameters were found to be signiﬁcantly reduced after chemotherapy. In conclusion, we
found that after the VAD therapy, the level of these cytokines which are thought to play an important role in the pathogenesis of
MM was signiﬁcantly suppressed. This is the ﬁrst study demonstrating strong impact of VAD treatment on circulating mediators of
sIL-2R and IL-8 levels parameters.
INTRODUCTION
Multiple myeloma (MM) is a B-cell malignancy char-
acterized by the accumulation of a clonal population of
plasma cells in the bone marrow that secretes a mon-
oclonal immunoglobulin protein. Bone marrow stromal
cells and myeloma cells produce several proinﬂamma-
tory cytokines that play an important role in the patho-
genesis of multiple myeloma. Of these, Interleukin-6 (IL-
6) is known as a growth and survival factor in multiple
myeloma via activation of extracellular signal-regulated
kinase and phosphatidylinositol 3-kinase signaling cas-
cade [1]. Another proinﬂammatory cytokine such as
Interleukin-1β (IL-1β), a potent osteoclast-activating fac-
tor, can increase the expression of adhesion molecules
and induce paracrine IL-6 production [2, 3]. These bio-
logic eﬀects of IL-1β closely parallel several of the clinical
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features of human myeloma, such as osteolytic bone le-
sions, homing of myeloma cells to the bone marrow, and
IL-6-induced cell growth [3]. Similar to IL-1β,t u m o r
necrosis factor-α (TNF-α) is also a potent bone-resorbing
proinﬂammatory cytokine that may contribute to the de-
velopment of the osteolytic bone disease observed in pa-
tients with MM [2, 4]. C-reactive protein (CRP) is pro-
ducedbyhepatocytesinresponsetoinﬂammationandin-
fection and strongly correlated with proinﬂammatory cy-
tokines particularly IL-6 [5]. On the other hand, soluble
interleukin-2 receptor (sIL-2R) can increase during some
inﬂammatory processes and malignant disorders [6, 7].
Levels of serum sIL-2R reﬂect the total amount of the ac-
tivated T lymphocytes in tumor-inﬁltrating lymphocytes
of cancer tissues and metastatic organs, because a part of
alpha-chain of sIL-2R is released into the bloodstream on
the attachment of IL-2 to its speciﬁc sIL-2R membrane
[7]. Interleukin-8 (IL-8) chemokine for neutrophils and
lymphocyte has been demonstrated to be produced by
bone marrow stromal cells [8]. Hypothesis suggested that
IL-8 may be able to attract circulating malignant plasma
cells precursors into an IL-6-rich bone marrow microen-
vironment [6]. Recently, high-dose therapy (HDT) with172 Irfan Kuku et al 2005:3 (2005)
autologous stem cell transplantation (auto-SCT) has be-
come the standard treatment for many patients with MM.
H e n c eH D Ta n da u t o l o g o u ss t e mc e l lr e s c u ea r ec o n -
sidered to be a standard part of initial therapy for pa-
tients with MM [9, 10]. Therefore, the patients accepted
as potential transplant candidates are generally treated
with dexamethasone-based programs rather than alkylat-
ing agents to avoid stem cell toxicity. Chemotherapy con-
sisting of VAD (vincristine-adriamycin-dexamethasone)
has commonly been used as the initial chemotherapeu-
tic regimen in MM patients prior to HDT and auto-SCT
[10, 11].
The objectives of the present study were to investigate
circulating levels of mediators such as IL-1β, sIL-2R, IL-6,
IL-8, TNF-α as well as CRP before treatment and in dif-
ferent time periods after VAD treatment in patients with
MM.
MATERIALS AND METHODS
This study involved a total of 14 newly diagnosed
MM patients who were admitted to the Department of
Hematology, Turgut Ozal Medical Center, Inonu Univer-
sity, Malatya, Turkey. They were 6 males (42%) and 8 fe-
males (58%). The mean age was 63.4 ± 10.8 (range 42–
71) years. The patients were in stage III of MM accord-
ing to the Durie-Salmon classiﬁcation. The study was car-
ried out in compliance with the guidelines prescribed by
the Institutional Health Committee at the Medical Fac-
ulty, Inonu University. All of the patients received VAD
and bisphosphonates (pamidronate) treatment following
diagnosis. Venous blood samples were taken before initia-
tionofVADtherapy(0day)andonthe3rd,7th,10th,and
28th days after the ﬁrst course of VAD. The VAD regimen
consisted of vincristine (0.4 mg/day for 4 days IV), dox-
orubicin (9mg/m2/day for 4 days IV), and dexametha-
sone (40mg/day per orally on days 1–4, 9–12, and 17–
20). The treatment cycles were repeated at 4-week inter-
vals.Noneofthepatientsorhealthycontrolswasreceiving
any topical or systemic medication on admission. Follow-
ing centrifugation of the blood samples at 2000xg for 10
minutes, sera were separated and kept at −70◦C until the
analysis of cytokines.
Cytokineanalysis
The analyses were performed using the Immulite
chemiluminescent enzyme immunometric assay (Diag-
nostic Products, Los Angeles, Calif). The technique was
based on a solid-phase (bead) two-site chemiluminescent
enzyme immunometric assay. For each cytokine calibra-
tion,amastercurvewasconstructedaccordingtoremarks
of the National Institute for Biological Standards and
manufacturer’s instructions. TNF-α assay has a calibra-
tion range of up to 1000pg/mL. The assay is standardized
in terms of the National Institute for Biological Standards
and Control reference preparation number 87/650. The
detection limit of the assay was approximately 1.7pg/mL.
IL-1β assay has a calibration range up to 1000pg/mL. The
assay is standardized in terms of the international stan-
dard for IL-1β, 86/680. The detection limit of the assay
was approximately 1.5pg/mL. sIL-2R assay has a calibra-
tion range up to 7200U/mL. The detection limit of the
assay is approximately 10U/mL. IL-6 assay has a calibra-
tion range up to 2000pg/mL. The assay is standardized in
terms of the international standard for IL-6, 89/548. The
detection limit of the assay was approximately 1pg/mL.
IL-8 assay has a calibration range up to 7500pg/mL. The
assay is standardized in terms of the National Institute for
Biological Standards and Controls reference preparation
number 89/520. The detection limit of the assay was ap-
proximately 2pg/mL. The coeﬃcient of variance of intra-
assay and interassay was generally in the range of 4.3%–
9.7%.
Statisticalanalysis
Mean and standard deviations were calculated for
each parameter. Variable normality analysis was per-
formed. Variables in Table 1 showed normal distribution
and comparison of means calculated by parametric un-
paired t test. Whereas parameters in Table 2 did not show
normal distribution and repeated measures, ANOVA test
was done. Pearson’s linear correlation test was used for
assessment of correlation between parameters. The mini-
mum level of signiﬁcance was deﬁned at P<. 05. All the
above-mentioned analysis was performed using the Stan-
dard Package for Social Sciences (SPSS) version 9.0 for
Windows (SPSS, Chicago, Ill).
RESULTS
The levels of cytokines and CRP were determined in
newly diagnosed patients prior to and after VAD ther-
apy. The results were expressed as means and standard
deviation (SD). Summaries of the concentrations of the
measured parameters prior to treatment are provided in
Table 1.PretreatmentcytokinelevelsandCRPwerefound
to be increased at diagnosis but signiﬁcantly decreased 3,
7 ,a n d1 0d a y sa f t e rV A Dt r e a t m e n t( Table 2). The de-
crease in cytokine levels temporarily the occurred since
the studied values started to increase on the 28th day after
VAD therapy. Average levels of TNF-α,I L - 1 β, sIL-2R, IL-
6, IL-8, and CRP diﬀered according to the days after con-
ducting VAD treatment. All cytokines except IL-1β were
foundtobepositivelycorrelatedwithCRP.Repeatedmea-
suresANOVAtestformeasuredcytokinesandCRPwithin
and between diﬀerent periods can be seen in Table 2.
DISCUSSION
The signiﬁcant point in this study is that serum lev-
els of IL-1β, sIL-2R, IL-6, IL-8, TNF-α, and CRP in newly
diagnosed stage III MM patients were signiﬁcantly higher
compared to normal controls and were signiﬁcantly lower
after chemotherapy. IL-6 is an important multifunctional2005:3 (2005) Proinﬂammatory Mediators in Multiple Myeloma 173
Table 1. Comparison of serum levels of cytokines and CRP (mean ±SD) in patients with MM.
Parameters Control Patients P value
TNF-α (pg/mL) 6.3 ±1.31 8 .6 ±3.7 P<. 0001
IL-1β (pg/mL) 4.3 ±0.21 0 .1 ±2.8 P<. 0001
sIL-2R (U/mL) 597 ±80 730 ±220 P = .021
IL-6 (pg/mL) 4.4 ±0.21 1 .4 ±3.2 P<. 0001
IL-8 (pg/mL) 6.4 ±1.62 3 .9 ±8.3 P<. 0001
CRP (mg/dL) 4.1 ±1.54 9 .9 ±19.4 P<. 0001
Table 2. Serum cytokines and CRP levels (mean ±SD) in diﬀerent periods after VAD treatment.
Periods TNF-α (pg/mL) IL-1β (pg/mL) sIL-2R (U/mL) IL-6 (pg/mL) IL-8 (pg/mL) CRP (mg/dL)
Before treatment (I) 18.6 ±3.71 0 .1 ±2.8 730 ±220 11.4 ±3.32 3 .9 ±8.34 9 .9 ±19.5
3 days after treatment (II) 13.6 ±4.36 .5 ±1.1 670 ±340 7.1 ±1.41 6 .2 ±5.92 5 .8 ±8.3
7 days after treatment (III) 11.9 ±3.95 .9 ±0.6 540 ±125 5.2 ±0.81 3 .5 ±4.23 .1 ±1.2
10 days after treatment (IV) 8.1 ±1.15 .9 ±0.6 436 ±28 4.6 ±0.55 .2 ±0.71 .8 ±2.5
28 days after treatment (V) 11.8 ±2.58 .8 ±2.7 779 ±97 7.5 ±1.28 .6 ±1.72 3 .9 ±10.9
Repeated measures
ANOVA P>. 05
II-V I-V, III-IV I-II, I-V,
II-III, II-V II-V, III-IV None II-V
Repeated measures
ANOVA P<. 05
Rest Rest Rest Rest All Rest
proinﬂammatory cytokine involved in tumor growth and
metastasis [12]. IL-6 is also the major growth and survival
factor for MM and has been shown to protect MM cells
from apoptosis induced by a variety of agents [13, 14].
Serum and bone marrow IL-6 levels were found to be el-
evated in myeloma patients, and levels correlate with dis-
ease activity and disease status [6]. CRP serum levels re-
ﬂect IL-6 in vivo and it may be regarded as a powerful
prognostic factor in patients with MM [5, 15]. TNF-α in-
creases in all types of cellular and humoral immune re-
sponse and shows a synergistic eﬀect with IL-6 [4, 16]. IL-
1β and TNF-α are also potent bone-resorbing cytokines
that may contribute to the development of the osteolytic
bone disease observed in patients with MM [2, 4]. In-
creased proinﬂammatory cytokines (IL-1β,I L - 6 ,T N F - α)
a n dC R Ps e r u ml e v e l sh a v eb e e nr e p o r t e di nd i ﬀerent se-
ries of MM patients [1, 2, 3, 4, 6, 17]. Similar to the pre-
vious ﬁndings from literature, our results showed that
these proinﬂammatory cytokines were higher in the MM
patients than control groups. Bisphosphonates seem to
have an anti-inﬂammatory activity caused by the inhibi-
tion of the release of inﬂammatory mediators from acti-
v a t e dm a c r o p h a g e s ,s u c ha sI L - 6 ,I L - 1 β,T N F - α, and CRP
[18, 19, 20, 21]. Several studies have demonstrated bis-
phosphonates to be powerful inhibitors of bone resorp-
tion [19, 20, 21]. According to our results, the combina-
tion of VAD/bisphosphonate chemotherapy produced a
signiﬁcant reduction of the circulating serum levels of the
cytokines.
There are suﬃc i e n td a t af o rs e r u mI L - 8a n ds I L -
2R levels of MM patients before and after treatment in
the literature. IL-8 plays a crucial role in inﬂammatory
and tumor-associated angiogenesis, as well as in tumor
progression [8, 22]. Bone marrow stromal cells (BMSC)
from myeloma patients also aberrantly secrete the
chemokine IL-8 [8, 23]. It is possible that this aber-
rant production of IL-8 by the BMSC of patients with
myelomadoesnothaveadirecteﬀectonmyelomagrowth
and survival per se but may instead function to promote
angiogenesis [8, 23, 24]. Nevertheless, according to liter-
ature reviews although some mediators were studied in
MM, sIL-2R, and IL-8 in particular, have not yet been
investigated in MM in relation to chemotherapy. High
levels of sIL-2R have been measured in many inﬂamma-
tory and malignant diseases [6, 7]. Although the speciﬁc
role of sIL-2R in the immune reponse has not yet been
fullydescribed,elevatedserumsIL-2Rlevelsarecorrelated
with MM activity and MM stage [25, 26]. Experimental
data from a study conducted by Vacca et al report that
serum and urinary values of sIL-2R were signiﬁcantly in-
creased in MM patients compared with normal controls
[26]. Our results showed that circulating serum levels of
the cytokines sIL-2R and IL-8 were increased in MM pa-
tients compared to controls and were positively correlated
with the other cytokines. Circulating serum levels of the
cytokines sIL-2R and IL-8 decreased signiﬁcantly follow-
ing chemotherapy. Our study is the ﬁrst one demonstrat-
ing reduction of circulating serum mediators, sIL-2R and
IL-8 levels, after chemotherapy.
In summary, our data also supported involvement of
several mediators in the pathogenesis of MM. Decreased
circulatingserummediatorsofsIL-2RandIL-8levelsmay
also give a preliminary idea of the assessment of therapy
response. Our results also suggest that after a time inter-
val (10–28 days), cytokine levels reincrease. This could
mean that cytokines suppression was temporary and one174 Irfan Kuku et al 2005:3 (2005)
VAD therapy course of recommended dose and period is
likely inadequate. Repeated VAD/bisphosphonate courses
may provide better cytokines suppression. So, more ef-
forts should be directed not only toward understanding
the signiﬁcance of the variability of these cytokines in pa-
tients with MM, but also their potential role in thera-
peutic approaches to MM. Further investigations are war-
ranted in larger patient groups to support our present
ﬁndings.
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